Tokyo, Jan. 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060273) titled 'Molecular subtyping of autism spectrum disorder using whole-cortex omics analysis' on Jan. 6.
Study Type:
Observational
Primary Sponsor:
Institute - National Center of Neurology and Psychiatry
Condition:
Condition - Autism spectrum disorder (ASD)
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - To analyze anonymized existing multi-omics data (bulk and single-cell transcriptomics, ATAC-seq, histone acetylation, DNA methylation, miRNA, etc.) from 11 cortical regions in ASD and control subjects stored in the PsychENCODE/NRGR database, and to characterize molecular subtypes of ASD across cortical regions and examine their associations with clinical and behavioral phenotypes.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 3
years-old
=
Gender - Male and Female
Key inclusion criteria - Anonymized existing data of individuals diagnosed with autism spectrum disorder (ASD) and healthy controls stored in the PsychENCODE Knowledge Portal managed by the NIMH Repository and Genomics Resource (NRGR), with available diagnostic assessments such as ADI-R and ADOS.
Key exclusion criteria - Cases lacking sufficient diagnostic information or having medical or genetic conditions deemed to substantially affect the validity of the analyses.
Target Size - 165
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2024 Year 06 Month 24 Day
Date of IRB - 2024 Year 07 Month 22 Day
Anticipated trial start date - 2024 Year 07 Month 22 Day
Last follow-up date - 2027 Year 03 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068945
Disclaimer: Curated by HT Syndication.
